Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.


Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Mistry, PK; Balwani, M; Baris, HN; Turkia, HB; Burrow, TA; Charrow, J; Cox, GF; Danda, S; Dragosky, M; Drelichman, G; El-Beshlawy, A; Fraga, C; Freisens, S; Gaemers, S; Hadjiev, E; Kishnani, PS; Lukina, E; Maison-Blanche, P; Martins, AM; Pastores, G; Petakov, M; Peterschmitt, MJ; Rosenbaum, H; Rosenbloom, B; Underhill, LH; Cox, TM

Published Date

  • July 2019

Published In

Volume / Issue

  • 77 /

Start / End Page

  • 101 - 102

PubMed ID

  • 31029022

Pubmed Central ID

  • 31029022

Electronic International Standard Serial Number (EISSN)

  • 1096-0961

Digital Object Identifier (DOI)

  • 10.1016/j.bcmd.2019.04.003


  • eng

Conference Location

  • United States